UK markets closed

Y-mAbs Therapeutics, Inc. (YMAB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
14.71-0.13 (-0.88%)
At close: 04:00PM EDT
14.85 +0.14 (+0.95%)
After hours: 07:05PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 643.96M
Enterprise value 566.74M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)7.57
Price/book (mrq)6.38
Enterprise value/revenue 6.68
Enterprise value/EBITDA -22.73

Trading information

Stock price history

Beta (5Y monthly) 0.76
52-week change 3138.41%
S&P500 52-week change 322.36%
52-week high 320.90
52-week low 34.60
50-day moving average 315.73
200-day moving average 39.01

Share statistics

Avg vol (3-month) 3391.46k
Avg vol (10-day) 3376.76k
Shares outstanding 543.78M
Implied shares outstanding 643.78M
Float 825.36M
% held by insiders 114.54%
% held by institutions 166.25%
Shares short (15 Apr 2024) 42.33M
Short ratio (15 Apr 2024) 46.85
Short % of float (15 Apr 2024) 46.38%
Short % of shares outstanding (15 Apr 2024) 45.32%
Shares short (prior month 15 Mar 2024) 42.1M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -25.26%
Operating margin (ttm)-13.69%

Management effectiveness

Return on assets (ttm)-9.84%
Return on equity (ttm)-20.39%

Income statement

Revenue (ttm)84.82M
Revenue per share (ttm)1.94
Quarterly revenue growth (yoy)-25.70%
Gross profit (ttm)N/A
EBITDA -20.45M
Net income avi to common (ttm)-21.43M
Diluted EPS (ttm)-0.49
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)78.64M
Total cash per share (mrq)1.8
Total debt (mrq)1.42M
Total debt/equity (mrq)1.40%
Current ratio (mrq)5.52
Book value per share (mrq)2.31

Cash flow statement

Operating cash flow (ttm)-27.23M
Levered free cash flow (ttm)-14.03M